An additional reason for proposing a MEK inhibitor in our immune therapy exposed patient is that in patients with NRAS mutant melanoma, MEK inhibitors showed a better response rate and progression-free survival (PFS) in immune therapy-exposed patients than in immune therapy-naïve patients in the NRAS-mutant melanoma (NEMO) trial [29]. This evidence concerns the gene MAP2K7 and melanoma.